Company: SXTPW
Filing Date: 2025-02-14
Form Type: S-1
Source: 0001213900-25-014334
Chunk: 309

Company: 60 DEGREES PHARMACEUTICALS, INC.
Filing Date: 2025-02-14
Form: S-1
Chunk 309
---
’s stock option activities:

| Options outstanding, December 31, 2022            |     | Number of 
 Options   |      - |     | Weighted 
 Average  
 Exercise 
 Price    |    - |     | Aggregate 
 Intrinsic 
 Value     | - |     | Weighted    
 Average     
 Remaining   
 Contractual 
 Life        
 (Years)     |    - |
|:--------------------------------------------------|:----|:----------|-------:|:----|:---------|-----:|:----|:----------|:--|:----|:------------|-----:|
| Granted                                           |     |           | 37,736 |     |          | 5.30 |     |           | - |     |             | 5.00 |
| Exercised                                         |     |           |      - |     |          |    - |     |           | - |     |             |    - |
| Forfeited                                         |     |           |      - |     |          |    - |     |           | - |     |             |    - |
| Expired                                           |     |           |      - |     |          |    - |     |           | - |     |             |    - |
| Options outstanding, December 31, 2023            |     |           | 37,736 |     | $        | 5.30 |     | $         | - |     |             | 4.53 |
| Options vested and exercisable, December 31, 2023 |     |           | 37,736 |     | $        | 5.30 |     | $         | - |     |             | 4.53 |

The aggregate intrinsic value in the table above reflects the difference between the Company’s closing stock price on the last trading day of the period and the exercise price of the options, multiplied by the number of in-the-money stock options. The intrinsic value of stock options changes based on the price of the Company’s common stock.

For the year ended December 31, 2023, the Company recognized $ 119,246of compensation expense related to stock option awards ( $0for the year ended December 31, 2022). No stock options were exercised, forfeited, or expired during the period presented. At December 31, 2023, the Company had no unrecognized share-based compensation expense related to unvested options.

The Company also has compensation agreements with two executives and a consultant,